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Lysophosphatidylcholine Mediates Melanocyte
Dendricity through PKCf Activation
Glynis A. Scott1, Manubu Arioka2 and Stacey E. Jacobs1
Melanocytes photoprotect the skin through transfer of melanin-containing melanosomes to keratinocytes.
Factors that increase melanocyte dendricity increase melanosome transfer, and are important for prevention of
skin cancer. Secretory phospholipase-A2 type X (sPLA2-X) is released by epidermal keratinocytes and we have
shown that lysophosphatidylcholine (LPC), the main lysophospholipid released in response to sPLA2-X activity,
stimulates melanocyte dendricity. LPC activates protein kinase C (PKC) and increases cAMP in other cells.
Treatment of melanocytes with sPLA2-X or LPC induced phosphorylation of the z isoform of PKC, and inhibition
of protein kinase C zeta (PKCz) activity abrogated LPC-dependent dendricity. We have shown previously that the
guanosine triphosphate-binding proteins Rac and Rho link hormone signaling and dendricity in melanocytes.
Treatment of melanocytes with LPC induced rapid activation of Rac that peaked at 30 minutes; Rho was also
activated, but peaked earlier and declined faster. Through the use of constitutively active mutants of Rac, we
show that PKCz activation is downstream of Rac. We conclude that the primary signaling pathway for LPC-
dependent dendrite formation in human melanocytes involves the activation of PKCz and that PKCz
phosphorylation is Rac dependent. Downstream mediators of LPC-dependent dendricity include Rac and Rho.
Journal of Investigative Dermatology (2007) 127, 668–675. doi:10.1038/sj.jid.5700567; published online 5 October 2006
INTRODUCTION
The growth factors, signaling intermediates, and effector
molecules involved in human melanocyte dendrite formation
are of interest because of the importance of dendricity in
melanosome transfer to keratinocytes. Secretory phospho-
lipases A2 (sPLA2) are a large family of small (14–18 kDa)
UV-inducible, calcium-dependent enzymes that liberate free
fatty acids such as arachidonic acid from the sn-2 position of
glycerophospholipids, producing lysophospholipids (Valentin
and Lambeau, 2000). In human keratinocytes, sPLA2-X is the
major secretory phospholipase produced and secreted by
keratinocytes (Schadow et al., 2001). We recently demon-
strated that sPLA2-X stimulates melanocyte dendricity and
activates tyrosinase, a key enzyme in melanin biosynthesis
(Scott et al., 2006). Further, we showed that lysopho-
sphatidylcholine (LPC), the predominant lysophospholipid
released from cell membranes following sPLA2-X activity,
mediates this effect. In the current report, we have examined
the second messenger pathways involved in LPC-dependent
dendricity in human melanocytes and describe a novel role
for the protein kinase C zeta (PKCz) isoform in this process.
LPC affects diverse aspects of cellular function including
atherogenesis, immune regulation, apoptosis, cell growth,
and cell migration (Cowan and Steffen, 1995; Lin and Ye,
2003; Kougias et al., 2005; Yang et al., 2005). Some of
the effects of LPC are mediated by its metabolite lysopho-
sphatidic acid, which is produced from LPC by the action
of lysophospholipase D (Aoki et al., 2002). LPC modulates
cell shape and induces dendrite formation in neuronal
cells (Nakashima et al., 2003b; Ikeno et al., 2005). We have
shown previously that very low doses of LPC (10–100 nM)
stimulate a 20–30% increase in the number of dendrites in
human melanocytes, making LPC comparable to a-melano-
cyte-stimulating hormone and endothelin-1 in its ability to
stimulate melanocyte dendricity (Hunt et al., 1994; Hara
et al., 1995; Scott et al., 2006). LPC activates protein kinase C
(PKC) and stimulates protein kinase A in other cell types
(Kugiyama et al., 1992; Bassa et al., 1999). The importance of
the PKC and protein kinase A second-messenger pathways for
regulation of the cytoskeleton in multiple cell types, and in
melanocytes in particular, are well recognized. The addition
of agents that increase cAMP, such as forskolin and
a-melanocyte-stimulating hormone, induce dendricity in
melanocytes, in part through the activation of the small
guanosine triphosphate (GTP)-binding protein Rac and
through inhibition of Rho (Busca et al., 1998; Scott and
Cassidy, 1998; Scott, 2002; Scott and Leopardi, 2003). The
effect of PKC activation on melanocyte dendricity is some-
what less clear, in part because melanocytes are often
cultured in media containing the potent PKC activator
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phorbol 12-myristate 13-acetate (12-O-tetradecanoylphorbol-
13-acetate (TPA)), that downregulate some PKC isoforms in
melanocytes as well as in other cell types (Oka et al.,
1995, 1996). In our experience, melanocytes grown in the
absence of TPA are epithelioid and have short dendrites, and
the addition of TPA to these cultures results in the elongation of
dendrites as well as new dendrite formation, consistent with
other reports (Brooks et al., 1991; Nakazawa et al., 1996).
Human melanocytes express the a, b, d, e, and z PKC
isoforms (Powell et al., 1993; Oka et al., 1995). As in other cell
types, specific functions for individual PKC isoforms are only
beginning to be defined, but in melanocytes, the PKCb isoform
has been reported to be involved in tyrosinase activation and
PKCz has been implicated as a signaling intermediate in
melanocyte proliferation and in inhibition of murine melano-
ma migration (Oka et al., 1995; Park et al., 1999; Sanz-
Navares et al., 2001). The PKCz isoform is of particular interest
as a potential mediator of melanocyte dendricity because it has
been implicated in cell migration and cytoskeletal reorganiza-
tion in other cell types, in part through phosphorylation of
profilin, and in determination of cell polarity (Izumi et al.,
1998; Sanz-Navares et al., 2001; Vemuri and Singh, 2001). Of
particular interest are reports of the association of PKCz with
the small GTP-binding proteins Rac and Cdc42. Rac and
Cdc42 are members of the Rho family of small GTP-binding
proteins that regulate cell shape, migration, and cell polarity
(Raftopoulou and Hall, 2004). In all cell types examined, Rac
stimulates lamellipodia formation, Cdc42 stimulates filopodia
formation, and Rho stimulates stress fiber formation (Ridley
et al., 1992). We have demonstrated that Cdc42 mediates
melanosome transfer in human melanocytes (Scott et al.,
2002), and that activation of Rac and inhibition of Rho
stimulate dendricity in melanocytic cells (Busca et al., 1998;
Scott and Cassidy, 1998; Scott, 2002; Scott and Leopardi,
2003). PKCz associates with the small GTP-binding protein
Cdc42 to mediate stress fiber loss and migration in astrocytes
(Etienne-Manneville and Hall, 2001), and activation of PKCz
has been shown to be downstream of Rac activation in certain
cell types including skeletal muscle (Qiu et al., 2000; Noda
et al., 2001; Liu et al., 2006). Therefore, PKCz association with
and coactivation by small GTP-binding proteins of the Rho
family are potentially interesting mediators of melanocyte
dendricity and melanosome transfer.
In this report, we first determined the upstream signaling
pathway(s) involved in LPC-dependent dendricity. We
analyzed the effect of LPC on activation of PKC isoforms
expressed by melanocytes and the potential effect of LPC on
the cAMP/protein kinase A pathway. We demonstrate that
sPLA2-X and its main lysophospholipid product LPC activates
PKCz, and that PKCz mediates LPC-dependent dendricity.
LPC did not regulate levels of cAMP in human melanocytes.
We then examined downstream mediators of LPC-dependent
dendricity and show that LPC activates both Rac and Rho.
Through the use of constitutively active mutants of Rac, we
show that LPC-dependent PKCz activation is downstream of
Rac activation. These results are the first to identify a specific
PKC isoform involved in melanocyte dendricity and to link
LPC with Rac activation.
RESULTS
sPLA2-X and LPC stimulate PKCf phosphorylation in human
melanocytes
Activation of PKC occurs through phosphorylation of its
kinase domain that regulates its activity (Mitchell et al.,
1989), so we analyzed the effects of recombinant sPLA2-X
and LPC on phosphorylation of PKCa/b, PKCd, PKCe, and
PKCz. Cells were placed in basal media lacking growth
factors and fetal calf serum for 1 hour before the addition of
either recombinant sPLA2-X (0.6 mg/ml) or LPC (100 nM).
These doses were chosen because they induce dendricity in
melanocytes within 48 hours. Melanocytes were treated with
either sPLA2-X or LPC for 15, 30, and 90 minutes, and total
cell lysates were resolved on 10% SDS-PAGE and blotted
with antibodies against phospho-PKC-a/b, phospho-PKCd,
phospho-PKCe, and phospho-PKCz. The z isoform of PKC was
consistently and reproducibly phosphorylated in response to
treatment (Figure 1a). Densitometry analysis of the blots
normalized to actin showed a 1.75-fold increase in PKCz
phosphorylation 15 minutes after sPLA2-X treatment, that
reached a 1.84-fold increase at 30 minutes (Figure 1b). Fold
change in PKCz phosphorylation following LPC treatment
was similar. The antibody used to detect phospho-PKCz also
recognizes phospho-PKCl. To ensure that we were not
detecting phospho-PKCl, melanocyte lysates were blotted
with polyclonal antibodies against PKCl. We confirmed
previous reports showing that melanocytes do not express this
PKC isoform (data not shown; Oka et al., 1995). We
confirmed that melanocytes express the a, b, d, and e
isoforms of PKC (as described previously (Oka et al., 1996))
by staining lysates with antibodies to the native proteins;
however no consistent pattern of phosphorylation was
observed in any other PKC isoform following LPC treatment
(data not shown).
sPLA2-X activity results in the release of large amounts of
LPC, smaller amounts of other lysophospholipids, and large
amounts of arachidonic acid (Bezzine et al., 2000). Our
previous study has shown that exogenous arachidonic acid
does not increase melanocytes dendricity (Scott et al., 2006).
As one test of the specificity of the effect of LPC on PKCz
phosphorylation, melanocytes were treated with arachidonic
acid (100 nM) and cell lysates were blotted for phospho-PKCz
(Figure 1c). In contrast with LPC, phosphorylation of PKCz
was not observed following treatment with arachidonic acid.
Because sPLA2-X activity releases both arachidonic acid and
LPC (Hanasaki et al., 1999; Murakami and Kudo, 2001),
we conclude that arachidonic acid does not contribute to
sPLA2-X-dependent PKCz phosphorylation.
Inhibition of PKCf activity abrogates LPC-induced dendricity in
human melanocytes
We next analyzed the effects of inhibition of PKCz activity on
LPC-induced dendricity in melanocytes. Cells were treated
with PKCz pseudosubstrate in the presence of LPC and
dendricity was determined (Figure 2a). PKCz pseudosubstrate
is a cell-permeable peptide that includes amino acids
113–125 of the pseudosubstrate region that maintains PKCz
in its inactive form and has an EC50 of 10–20 mM. PKCz
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pseudosubstrate selectively inhibits PKCz without affecting
other PKC isoforms (Chen et al., 2002). Consistent with our
previous studies examining the effects of LPC on melanocyte
dendricity, the addition of LPC (100 nM) to melanocytes
for 48 hours induced a significant increase in the number of
cells with greater than two dendrites. Only 22% of cells
treated with diluent alone had more than two dendrites,
whereas over half of cells treated with LPC had more than
two dendrites. The addition of PKCz pseudosubstrate, even
at very low doses, abrogated LPC-induced dendricity.
To confirm that PKCz pseudosubstrate blocked PKCz
phosphorylation, cells in basal medium were pretreated with
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Figure 1. sPLA2-X and LPC, stimulate phosphorylation of PKCf in melano-
cytes. (a) Human melanocytes were treated with either recombinant sPLA2-X
(0.6 mg/ml) or LPC (100 nM), and cell lysates were resolved in 10% SDS-PAGE
and blotted with antibodies against PKCz phosphorylated on threonine 410.
Approximately, 35 mg of protein was resolved on each lane. Blotting for
b-actin protein assessed loading of the lanes. Within 15 minutes of treatment
with sPLA2-X or LPC, phosphorylated PKCz was detected and persisted at
90 minutes. Results are representative of at least three separate experiments
on pooled cultures from melanocytes cultured from three separate foreskins.
(b) Densitometry analysis from three separate experiments normalized against
b-actin, averaged and represented as fold change compared with control
cells7standard deviation. At 30 minutes, a 2-fold change in activated
PKCz was seen in LPC- and sPLA2-X-treated cells and at 90 minutes, activated
PKCz remained elevated (1.5-fold). (c) The effect of arachidonic acid on
PKCz phosphorylation was assessed. Melanocytes were treated with
arachidonic acid (100 nM) for the indicated times and lysates were blotted
for phospho-PKCz as described above. In contrast with sPLA2-X and LPC,
arachidonic acid did not induce PKCz phosphorylation. Results shown
are representative of two separate experiments in which pooled cultures
from four separate foreskins were analyzed.
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Figure 2. Inhibition of PKCf blocks LPC-dependent dendricity in
melanocytes. (a) Human melanocytes were treated with LPC in the presence
of PKCz pseudosubstrate and dendricity was analyzed 48 hours later.
Cells treated with LPC showed the expected increase in dendricity, with
450% of the cells extending more than two dendrites compared with only
22% of cells treated with diluent alone. The addition PKCz pseudosubstrate
induced a dose-dependent decrease in dendricity with elimination of
essentially all LPC-dependent dendricity at a dose of 500 nM. Results represent
the average of three separate experiments in which pooled cells from
three separate foreskin cultures were used, 7standard deviation. Asterisks
indicate statistical significance between LPC-treated cells and cell treated
with LPC and inhibitor (Po0.05). (b) To confirm that PKCz pseudosubstrate
inhibits LPC-dependent PKCz phosphorylation, cells were either pre-treated
with PKCz pseudosubstrate (500 nM) then treated with LPC (100 nM), or
treated with LPC in the absence of inhibitor for 30 and 90 minutes. Cells
treated with inhibitor alone served as negative controls. Lysates were resolved
on 10% SDS-PAGE and blotted with antibodies against phospho-PKCz.
b-Actin served as a loading control. The expected increase in PKCz
phosphorylation is observed following treatment with LPC. Phosphorylation
is completely abrogated by the presence of PKCz pseudosubstrate.
(c) Representative images of hematoxylin-stained cells grown on coverslips
and treated with diluent (Control), LPC (100 nM), or LPC and PKCz
pseudosubstrate (500 nM). LPC-treated cells exhibit long arborizing
dendrites that are eliminated in the presence or PKCz pseudosubstrate.
Bar¼10 mm.
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PKCz pseudosubstrate (50 nM) for 2 hours and treated with
LPC (100 nM) for 30 minutes or 90 minutes and PKCz
phosphorylation was assessed (Figure 2b). Controls consisted
of cells treated with inhibitor alone. As expected, treatment
with LPC induced phosphorylation of PKCz at 30 and
90 minutes. The presence of PKCz pseudosubstrate blocked
the ability of LPC to induce PKCz phosphorylation. Repre-
sentative photographs of melanocytes treated with diluent
alone (Control), LPC (100 nM), or LPCþ PKCz pseudosub-
strate are shown in Figure 2c. Cells treated with diluent are
predominantly bi-polar, whereas 48 hours after treatment
with LPC many of the melanocytes have long complex
dendrites. The inclusion of PKCz pseudosubstrate blocked
LPC-induced dendricity and resulted in cells with a pre-
dominantly bi-polar phenotype.
LPC has no effect on levels of cAMP in melanocytic cells
Melanocytes were treated with a wide range of doses of LPC
(10, 50, and 100 nM and 1 mM) and levels of cAMP were
quantitated at 1, 5, and 10 minutes, as described in Materials
and Methods. As a positive control, cells were treated
with forskolin (20 mM). Cells treated with forskolin showed
the expected increase in cAMP (up to 164 pmol/ml
after 10 minutes of treatment). In contrast, treatment with
LPC had no effect on cAMP levels, even at high doses (1 mM,
Table 1).
LPC activates Rac and Rho in melanocytes
We next determined whether LPC regulates the activity of
Rac and Rho in human melanocytes. Melanocytes were
placed in basal medium (modified chemically defined
medium-153) for 2 hours and were then treated with LPC
(100 nM), and GTP-bound Rac or GTP-bound Rho was
isolated from cell lysates. Activated Rac was affinity purified
from lysates using agarose beads conjugated to p21-activated
kinase-binding domain, followed by Western blotting.
Activated Rho was detected using an ELISA plate assay in
which GTP-Rho in lysates bound to Rhotekin immobilized to
ELISA plates, followed by detection of bound protein with
Rho-specific antibodies. Controls consisted of cells treated
with diluent; for Rac activation assays, lysates loaded with
non-hydrolyzable GTP (GTPgS) served as positive controls.
For Rho activation assay, recombinant GTP-bound Rho
protein served as a positive control.
Unstimulated cells had little or no detectable GTP-bound
Rac, but treatment with LPC resulted in activation of Rac at
1 minute that peaked at 30 minutes (Figure 3a), similar to the
timing of activation of PKCz. The average fold change in
active Rac, normalized against total Rac, obtained from
densitometry analysis (n¼ 3 experiments) is shown in Figure
3b. At 1 minute, GTP-Rac increased 1.6-fold over controls
and at 30 minutes following LPC treatment the increase in
GTP-Rac over control levels peaked at 1.9-fold. One hour
following LPC treatment, levels of activated Rac remained
elevated (1.5-fold). Rho was also activated following LPC
treatment, increasing 1.5-fold at 1 minute, similar to LPC
effects on Rac activation. In contrast with Rac, however, Rho
activation peaked earlier (5 minutes) and declined to baseline
levels by 60 minutes, at a time when Rac activity was still
elevated.
Rac activates PKCf in melanocytes
Several reports indicate that activation of PKCz occurs
downstream of Rac and that PKCz colocalizes with Cdc42
(Qiu et al., 2000; Noda et al., 2001; Liu et al., 2006). To
determine if Rac or Cdc42 activates PKCz in melanocytes,
cells were infected with adenovirus vectors (100ml of
infectious supernatant from human embryonic kidney 293
cells) expressing constitutively active Rac (V12Rac), constitu-
tively active Cdc42 (V12Cdc42), or empty vector on days 1, 3,
and 4, and on the 5th day cell lysates were blotted for
phosphorylated PKCz. Infection efficiency was monitored by
viewing the cells under fluorescent light for detection of
green fluorescence protein, which is coexpressed by a
separate promoter with the recombinant protein. The infec-
tion protocol resulted in approximately 90% infection
efficiency. On the day of the experiment, cells were placed
in basal medium without growth factors for 2 hours. Blotting
for phosphorylated PKCz showed that expression of activated
Rac, but not activated Cdc42, resulted in enhanced PKCz
activation compared with vector-expressing cells (Figure 4).
DISCUSSION
Secretory phospholipases participate in membrane remodel-
ing and breakdown and in the release of bioactive molecules
such as LPC that have wide-ranging cellular functions. Recent
reports have shown that LPC is a positive regulator of dendrite
formation in PC12 cells (Ikeno et al., 2005). Prior data from
our laboratory established that LPC is a potent positive
regulator of human melanocyte dendricity, inducing a robust
increase in dendrite formation within 48 hours of treatment
even at very low doses (nanomolar range). Our data
Table 1. cAMP (pmol/ml) in human melanocytes
treated with LPC for 1 min, 5 min, or 10 min
pmol/ml SD
Control 2.047 0.072
1 min 10 nM 2.658 0.077
100 nM 2.131 0.072
1,000 nM 2.89 0.08
Forskolin 54.153 1.9
5 min 10 nM 2.704 0.079
100 nM 2.704 0.079
1,000 nM 2.75 0.079
Forskolin 85.125 5.5
10 min 10 nM 3.901 0.093
100 nM 2.89 0.081
1,000 nM 1.841 0.069
Forskolin 164.433 14.5
LPC, lysophosphatidylcholine.
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demonstrate that sPLA2-X and LPC activate PKCz in human
melanocytes. The level of activated PKCz in non-stimulated
melanocytes varied among individual experiments, but was
generally low. Arachidonic acid, which we have shown
previously does not stimulate dendrite formation in melano-
cytes, had no effect on PKCz activation. Prior studies have
shown that arachidonic acid stimulates activation of conven-
tional PKC isoforms, in part through Caþ2-dependent binding
of arachidonic acid to the C2 domain of the enzyme (Lopez-
Nicolas et al., 2006). Although the mechanisms of activation
of PKC by arachidonic acid are complex and still poorly
understood, the lack of a C2 domain within the PKCz isoform
may explain the inability of arachidonic acid to activate PKCz
in melanocytes and to stimulate melanocyte dendricity. In
serum, LPC is metabolized to lysophosphatidic acid through
the action of lysophospholipase D, and keratinocytes
produce lysophospholipase D in blister fluid (Aoki et al.,
2002; Mazereeuw-Hautier et al., 2005). Although expression
of lysophospholipase D has not been evaluated in human
melanocytes, we cannot exclude the possibility that effects
of exogenous LPC added to melanocyte cultures could
be mediated through lysophosphatidic acid. Analysis of
lysophospholipase D expression in melanocytes and effects
of lysophosphatidic acid on melanocyte dendricity will be
necessary to assess this. Through the use of PKCz pseudo-
substrate, we show that the ability of LPC to induce dendricity
is dependent upon PKCz activation. Our prior studies have
shown that activation of Rac results in dendricity in melano-
cytic cells. In this study, we have identified Rac and Rho
as downstream mediators of LPC-dependent dendricity and
have linked Rac activation with PKCz activation.
PKCz is an important signaling intermediate that regulates
the cytoskeleton, leading to changes in cell migration and
neurite extension in response to nerve growth factor (Cole-
man and Wooten, 1994; Wooten et al., 1994; Gomez et al.,
1995; Vemuri and Singh, 2001). In murine melanoma cells,
PKCz expression is inversely correlated with both melanin
content and cell migration (Sanz-Navares et al., 2001) and in
a single study with human melanocytes, activation of PKCz
has been suggested to play a role in melanocyte proliferation
(Oka et al., 1995). The addition of PKCz pseudosubstrate
completely blocked the ability of LPC to induce dendricity
in melanocytes, suggesting that PKCz activation is the
Expresssion of phospho-PKC in melanocytes
expresssing activated Rac or activated Cdc42
V V12Rac V12Cdc42
76 kDa
 -Actin
Figure 4. Rac activates PKCf in human melanocytes. Melanocytes expressing
V12Rac, V12Cdc42, or vector (V) were lysed, resolved on 10% SDS-PAGE and
blotted with antibodies against phospho-PKCz. An increase in phospho-PKCz
is present in cells expressing V12Rac compared with cells expressing vector
alone. Constitutive activation of Cdc42 did not result in enhanced
phosphorylation of PKCz. Results shown are representative of two separate
experiments in which pooled melanocyte cultures from seven individual
foreskins were analyzed.
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Densitometry analysis of affinity purified GTP-Rac in LPC-treated melanocytes
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Figure 3. LPC activates Rac and Rho in human melanocytes. (a) Cells
were treated with LPC for the indicated time points and activated Rac was
isolated from cell lysates by incubation with agarose beads coupled with
p21-activated kinase-binding protein. Complexes were resolved in 15%
SDS-PAGE and blotted for Rac. A portion of the lysate was blotted for total
Rac protein. Positive controls consisted of lysates loaded with GTPgS.
Activation of Rac was observed at 1 minute and peaked at 30 minutes.
Levels of activated Rac began to decline at 60 minutes. Results shown are
representative of three separate experiments in which melanocytes from four
individual foreskins were pooled and analyzed. (b) Densitometry analysis of
the blots shows that levels of GTP-bound Rac reached a maximum at
30 minutes with a near 2-fold increase over diluent treated controls. Each bar
represents the fold change in active Rac normalized against total Rac from the
three experiments, 7standard deviation. (c) Rho activation, measured using
an ELISA assay, occurred 1 minute following LPC treatment and peaked at
5 minutes with a 5.3-fold increase in activated Rho. By 60 minutes, levels
of activated Rho had returned to baseline. Results are representative of two
separate experiments in which triplicate samples were analyzed
(7standard deviation).
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primary signaling pathway involved in LPC-induced dendrite
formation in melanocytes. To our knowledge, this is the first
report to link a specific PKC isoform with dendricity in
melanocytic cells.
We have postulated in the past that the balance between
levels of activated Rac, which stimulates dendricity, and
activated Rho, that inhibit melanocyte dendricity, regulates
the length and number of dendrites in human melanocytes
(Scott, 2002). Our previous data also showed that, similar to
other cell types, a hierarchy of signaling among Rho proteins
occurs in melanocytes, with Rac activation leading to Rho
activity (Ridley et al., 1992; Scott and Leopardi, 2003). Our
data demonstrate that LPC activates both Rac and Rho in
human melanocytes. Similar to recent reports, we also found
that PKCz activation is downstream of Rac activation because
expression of V12Rac enhanced PKCz phosphorylation in
melanocytes. Rac and Rho activation both occurred within
1 minute of LPC treatment, but Rho activation peaked earlier
than Rac activation (5 vs 30 minutes). The absolute fold
change in the amount of active Rho was considerably higher
than active Rac following LPC treatment (5.2-fold at
5 minutes vs 1.9-fold at 30 minutes, respectively). However,
differences in assays preclude definite interpretation of
relative levels of Rac and Rho activation. We chose to use
an ELISA-based assay for the analysis of Rho activation
because of the high sensitivity of the assay and the need for
only small amount (40–50 mg) of protein, compared with
more traditional pulldown assays in which large amounts
(300 mg) are required. Because melanocytes have a low
proliferative rate, particularly in media lacking TPA, this is a
critical consideration. At the present time, a similar ELISA-
based assay for Rac activation is not available. Our results
show that Rac activation in LPC-treated cells at 30 minutes
was comparable to levels of GTP-Rac in lysates loaded with
GTPgS in which over 90% of Rac is in the active state. Thus,
we think it is likely that Rac activation was substantial in
response to LPC and that the balance between Rac and Rho
activation stimulated by LPC will be critically important for
LPC-dependent dendricity in melanocytes. Future experi-
ments, beyond the scope of this report, using dominant-
negative Rac and Rho mutants will be necessary to determine
the significance of Rac and Rho activation in LPC-dependent
dendricity.
The identification of PKCz as a signaling intermediate of
melanocyte dendricity may help to explain a seeming
contradiction in linking PKC activation with melanocyte
dendrite formation. Melanocytes grown in media containing
TPA are highly dendritic, despite the known downregulation
of multiple PKC isoforms expressed by melanocytes by
chronic exposure to TPA. Isoforms known to be down-
regulated in melanocytes include the a, b, d, and e isoforms,
but not the z isoform (Oka et al., 1995). It is generally
assumed that PKCz is insensitive to TPA because it contains
only one of the two cysteine-rich zinc finger motifs in the C1
domain necessary for phorbol ester binding (Ono et al.,
1989). However, Oka et al. (1995) showed that treatment of
human melanocytes with TPA increased PKCz activity in the
cytosol and particulate fractions, and in neural cells, TPA has
also been shown to activate PKCz (Wooten et al., 1994; Oka
et al., 1995). Therefore, it is possible that TPA-dependent
dendricity in human melanocytes is due to PKCz activation.
Experiments are being performed to evaluate this possibility.
MATERIALS AND METHODS
Reagents
Vitrogen 100 was purchased from Cohesion (Palo Alto, CA); the BCA
Protein Assay kit was purchased from Pierce Chemical (Rockford,
IL). The PKCz pseudosubstrate inhibitor Myr-SIYRRGARRWRKL-OH
was purchased from Calbiochem (San Diego, CA). LPC (Palmitoyl)
and arachidonic acid were purchased from Sigma Co. (St Louis,
MO). Polyclonal antibodies to phospho-PKC a/bII, phospho-PKCd
and mAbs to phospho-PKCz/l were purchased from Cell Signaling
Technology (Beverly, MA). Polyclonal antibodies to b-actin were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); horse-
radish peroxidase-conjugated goat anti-mouse and goat anti-rabbit
antibodies were purchased from Sigma Co.
Generation of recombinant sPLA2-X
Full-length cDNA coding for mouse group X sPLA2 has been
described previously (Nakashima et al., 2003b). The cDNA was
expressed from a pMT vector (a derivative of pME185) that
allows expression of the recombinant protein with a C-terminal
hemagglutinin tag and with a stretch of six histidines.
The recombinant protein contains the sequence DLYPYDVP-
DYASHHHHHH (hemagglutinin epitope is underlined) as
a C-terminal extension. Isolation of recombinant sPLA2-X was
performed on Niþ 2 columns as described previously (Nakashima
et al., 2003a). Elutions from the column were resolved on 15%
SDS-PAGE and after transfer to nitrocellulose membranes
(BioRad, Hercules, CA), membranes were probed with mAbs to
hemagglutinin (Santa Cruz Biotechnology). A single band of
B17.5 kDa was present in elution fractions 1 and 2 by Western
blotting and on Coomassie-stained gels. The activity of recombinant
sPLA2-X was quantitated using sPLA2 Activity kit (Assay Designs,
Ann Arbor, MI), which is based on a synthetic sPLA2 substrate
diheptanoylthiophosphorylcholine. For all experiments, sPLA2-X
was used at an activity of 0.01 U/ml that corresponds to 600 ng/ml
protein concentration.
Adenoviral vectors
Recombinant adenoviral vectors capable of expressing constitutively
active Rac (V12Rac) and Cdc42 (V12Cdc42) were a generous gift of
Dr. James Bambara (University of Colorado, Denver, CO) and have
been described previously (Brown et al., 2000). Infectious virus was
amplified in human embryonic kidney 293 cells (ATCC, Rockville,
MD). Each recombinant vector contains a cDNA for green
fluorescence protein for monitoring infection efficiency. Green
fluorescence protein and Rac and Cdc42 cDNAs were driven from
separate cytomegalovirus promoters.
Cells and cell culture
Neonatal foreskins were obtained according to the University of
Rochester Research Subjects Review Board guidelines and were the
source of cultured human melanocytes. To avoid suppression of PKC
isoform expression owing to chronic exposure to TPA, melano-
cytes were cultured in modified chemically defined medium-153
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supplemented with 1.5% fetal bovine serum, insulin (5 mg/ml), basic
fibroblast growth factor (0.6 ng/ml), a-melanocyte-stimulating hor-
mone (10 nM), and endothelin-1 (10 nM). COS-1 (ATCC) and human
embryonic kidney 293 cells were maintained in DMEM with 10%
fetal bovine serum. All reagents were purchased from Sigma Co.,
except for fetal bovine serum that was purchased from Cellgro
(Herndon, VA).
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer (150 mM
NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, and 50 mM Tris-HCl) with
protease inhibitors (Boehringer Mannheim, Gmbt, Germany). For
analysis of phospho-PKC, phosphatase inhibitors were added to the
radioimmunoprecipitation assay buffer (Phosphatase Inhibitor Cock-
tail Set II, Calbiochem). Protein was quantitated using BSA as standard
(Bio-Rad Laboratories, Hercules, CA) and protein was resolved on
10% SDS-PAGE gels and blotted using standard procedures.
Visualization of the immunoreactive proteins was accomplished
with an enhanced chemiluminescence reaction (Pierce Chemical,
Rockford, IL). Densitometry analysis was performed on digital images
using National Institutes of Health Image 1.63 software.
Rac and Rho activation assay
Activated Rac was isolated from melanocyte cell lysates using a
Rac1 Activation Assay kit (Upstate Cell Signaling Solutions, Lake
Placid, NY). For analysis of effects of LPC on Rac activation,
melanocytes (approximately 2 107) were placed in basal media
without growth factors for 2 hours and were then treated with LPC
(100 nM) for various time points. Controls consisted of cells treated
with diluent. Activated (GTP-bound) Rac was isolated from cell
lysates after equalization of protein according to manufacturer’s
instructions. Total Rac was analyzed by Western blotting as an
added control. Samples were immunoblotted on 15% SDS-PAGE
gels for Rac using standard procedures. Activated Rho was isolated
from melanocyte cell lysates using a G-LISA RhoA Activation Assay
Biochem Kit (Cytoskeleton Inc., Denver, CO). Melanocytes (ap-
proximately 2 105) were placed in basal media without growth
factors for 2 hours and were then treated with LPC (100 nM) for
various time points. Controls consisted of cells treated with diluent.
Lysates (40 mg) were aliquoted in triplicate onto ELISA plates pre-
coated with Rho-GTP-binding domain (Rhotekin) and activated Rho
was determined according to manufacturer’s instructions.
cAMP assays
Primary human melanocytes (4.0 105 cells/well) were cultured in
six-well plates. At the time of the assay, media were replaced with
serum- and growth factor-free pre-warmed modified chemically
defined medium-153 for 1 hour before the addition of LPC. Fifteen
minutes before the addition of LPC, isobutyl-methyl-xanthine (1 mM;
Sigma Co.) was added to inhibit phosphodiesterase activity and was
present in the media throughout the experiment. Positive controls
consisted of cells treated with forskolin (20 mM). cAMP levels were
measured using the Direct Cyclic AMP EIA kit with acetylation as per
manufacturer’s instructions (Assay Design Inc., Ann Arbor, MI). The
plate was read on a FinstrumentTM microplate Reader (MTX Lab Inc.,
Vienna, VA) and the data were analyzed with DeltasoftTM 3 software
(BioMetallics Inc., Princeton, NJ) using a weighted four-parameter
logistic curve-fitting program.
Melanocyte dendricity assay
Melanocytes (105) were subcultured onto vitrogen-coated coverslips
and were treated with LPC with or without PKCz pseudosubstrate for
48 hours. Controls consisted of cells treated with comparable
volumes of diluent as well as with inhibitor alone. Following
treatment, cells were fixed in 3.7% formalin/phosphate-buffered
saline, stained with hematoxylin and digital photographs were taken
using Spot Digital camera software (Diagnostics Instruments, Sterling
Heights, MI). The number of dendrites per cell was determined for
approximately 100 cells from each experiment.
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